New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Academic Article uri icon

Overview

abstract

  • Malignant pleural mesothelioma (MPM) is a highly lethal cancer with limited therapeutic options. Recent work has focused on the frequent somatic inactivation of two tumor suppressor genes in MPM-NF2 (Neurofibromatosis type 2) and the recently identified BAP1 (BRCA associated protein 1). In addition, germline mutations in BAP1 have been identified that define a new familial cancer syndrome, which includes MPM, ocular melanoma, and other cancers. These recent advances may allow screening of high-risk individuals and the development of new therapies that target key pathways in MPM.

publication date

  • July 23, 2012

Research

keywords

  • Mesothelioma
  • Neurofibromatosis 2
  • Tumor Suppressor Proteins
  • Ubiquitin Thiolesterase

Identity

PubMed Central ID

  • PMC3432735

Scopus Document Identifier

  • 84865720268

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-11-2375

PubMed ID

  • 22825583

Additional Document Info

volume

  • 18

issue

  • 17